Mobile App

Google Play Apple Store
Podcasts in NSCLC Harboring EGFR Mutations: Cutting-Edge Reports from ASCO 2024
AMA/ABS/ANCC - Podcasts
Precision therapy has revolutionized the treatment of lung cancer and has made personalized treatment a reality. To this end, the therapeutic landscape for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations has been evolving rapidly. Indeed, ongoing studies are investigating novel agents and combinations that will play a role in earlier and subsequent treatment settings of EGFR mutated NSCLC and are also exploring the utility of additional biomarkers in guiding therapy in EGFR mutated advanced NSCLC. Considering a continual influx of such progress from ongoing trials, clinicians and healthcare professionals will need guidance from key opinion leaders in sifting through recent evidence and identifying practice-changing updates.

This podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.
Review the activity to claim AMA/ABS/ANCC credit after completion of the brief Post-Test/Evaluation(s).

Stephen Liu, MD Stephen Liu, MD
Associate Professor of Medicine
Director of Thoracic Oncology
Director of Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Supported by an independent educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Launch Date: June 5, 2024
Release Date: June 5, 2024
Expiration Date: May 31, 2025

Mini Module
ACC_Conference_EGFR-Mutated NSCLC_Podcast(1730x162).png


Change Settings